Allogene Therapeutics Investor Relations Material
Latest events
Q4 2023
Allogene Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Allogene Therapeutics Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Collaboration revenue - related party
Expenses by
Financials
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It is developing UCART19, an investigational chimeric antigen receptor T cell product candidate for the treatment of CD19 expressing hematological malignancies; and ALLO-501, an investigational alloCAR T product candidate for the treatment of B-cell non-Hodgkin lymphoma. The company was formerly known as Allogen BioPharma, Inc. and changed its name to Allogene Therapeutics, Inc. in June 2018. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Key slides for Allogene Therapeutics Inc
Investor Presentation
Allogene Therapeutics Inc
Investor Presentation
Allogene Therapeutics Inc
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States